FIGURE 6 from Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma

Dosing with a combination of tolinapant plus decitabine drives increased efficacy in necroptosis-model of TCL (EL4-C8KO model). Volumes of EL4-PAR (A) and C8KO (B) EL4 tumors in wild-type mice treated with decitabine (0.3 mg/kg i.p., every day × 3 doses) and tolinapant dosing (25 mg/kg orally, every day × up to 46 doses) as single agents or in combination. C, Kaplan–Meier plot showing survival (tumors reaching 1,000 mm³ as endpoint) of mice bearing EL4-C8KO (C8KO) tumors.